|
1
|
Tiikkainen M, Häkkinen AM, Korsheninnikova
E, Nyman T, Mäkimattila S and Yki-Järvinen H: Effects of
rosiglitazone and metformin on liver fat content, hepatic insulin
resistance, insulin clearance, and gene expression in adipose
tissue in patients with type 2 diabetes. Diabetes. 53:2169–2176.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sardone LD, Renlund R, Willett TL, Fantus
IG and Grynpas MD: Effect of rosiglitazone on bone quality in a rat
model of insulin resistance and osteoporosis. Diabetes.
60:3271–3278. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Falchetti A, Masi L and Brandia ML:
Thiazolidinediones and bone. Clin Cases Miner Bone Metab.
4:103–107. 2007.PubMed/NCBI
|
|
4
|
Kumar S, Hoffman SJ, Samadfam R, Mansell
P, Jolette J, Smith SY, Guldberg RE and Fitzpatrick LA: The effect
of rosiglitazone on bone mass and fragility is reversible and can
be attenuated with alendronate. J Bone Miner Res. 28:1653–1665.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ettinger MP: Aging bone and osteoporosis:
Strategies for preventing fractures in the elderly. Arch Intern
Med. 163:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iglesias JE, Salum FG, Figueiredo MA and
Cherubini K: Important aspects concerning alendronate-related
osteonecrosis of the jaws: A literature review. Gerodontology.
32:169–178. 2015. View Article : Google Scholar
|
|
7
|
Piscitelli P, Auriemma R, Neglia C and
Migliore A: Alendronate: New formulations of an old and effective
drug to improve adherence avoiding upper gastrointestinal side
effects. Eur Rev Med Pharmacol Sci. 18:3788–3796. 2014.
|
|
8
|
Howard PA, Barnes BJ, Vacek JL, Chen W and
Lai SM: Impact of bisphosphonates on the risk of atrial
fibrillation. Am J Cardiovasc Drugs. 10:359–367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brown JP, Morin S, Leslie W, Papaioannou
A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse
R, et al: Bisphosphonates for treatment of osteoporosis: Expected
benefits, potential harms, and drug holidays. Can Fam Physician.
60:324–333. 2014.PubMed/NCBI
|
|
10
|
Liao HT and Chen CT: Osteogenic potential:
Comparison between bone marrow and adipose-derived mesenchymal stem
cells. World J Stem Cells. 6:288–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murphy MB, Moncivais K and Caplan AI:
Mesenchymal stem cells: Environmentally responsive therapeutics for
regenerative medicine. Exp Mol Med. 45:e542013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
James AW: Review of signaling pathways
governing MSC osteogenic and adipogenic differentiation.
Scientifica (Cairo). 2013:6847362013.
|
|
13
|
Westin S, Kurokawa R, Nolte RT, Wisely GB,
McInerney EM, Rose DW, Milburn MV, Rosenfeld MG and Glass CK:
Interactions controlling the assembly of nuclear-receptor
heterodimers and co-activators. Nature. 395:199–202. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kang Q, Song WX, Luo Q, Tang N, Luo J, Luo
X, Chen J, Bi Y, He BC, Park JK, et al: A comprehensive analysis of
the dual roles of BMPs in regulating adipogenic and osteogenic
differentiation of mesenchymal progenitor cells. Stem Cells Dev.
18:545–559. 2009. View Article : Google Scholar
|
|
15
|
Viccica G, Francucci CM and Marcocci C:
The role of PPARγ for the osteoblastic differentiation. J
Endocrinol Invest. 33(Suppl 7): 9–12. 2010.
|
|
16
|
Rhinn M and Dollé P: Retinoic acid
signalling during development. Development. 139:843–858. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maden M: Retinoic acid in the development,
regeneration and maintenance of the nervous system. Nat Rev
Neurosci. 8:755–765. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pogenberg V, Guichou JF, Vivat-Hannah V,
Kammerer S, Pérez E, Germain P, de Lera AR, Gronemeyer H, Royer CA
and Bourguet W: Characterization of the interaction between
retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers
and transcriptional coactivators through structural and
fluorescence anisotropy studies. J Biol Chem. 280:1625–1633. 2005.
View Article : Google Scholar
|
|
19
|
Liu Y, Liu Y, Zhang R, Wang X, Huang F,
Yan Z, Nie M, Huang J, Wang Y, Wang Y, et al: All-trans retinoic
acid modulates bone morphogenic protein 9-induced osteogenesis and
adipogenesis of preadipocytes through BMP/Smad and Wnt/β-catenin
signaling pathways. Int J Biochem Cell Biol. 47:47–56. 2014.
View Article : Google Scholar
|
|
20
|
Zhang W, Deng ZL, Chen L, Zuo GW, Luo Q,
Shi Q, Zhang BQ, Wagner ER, Rastegar F, Kim SH, et al: Retinoic
acids potentiate BMP9-induced osteogenic differentiation of
mesenchymal progenitor cells. PLoS One. 5:e119172010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang JH, Liu YZ, Yin LJ, Chen L, Huang J,
Liu Y, Zhang RX, Zhou LY, Yang QJ, Luo JY, et al: BMP9 and COX-2
form an important regulatory loop in BMP9-induced osteogenic
differentiation of mesenchymal stem cells. Bone. 57:311–321. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang J, Yuan SX, Wang DX, Wu QX, Wang X,
Pi CJ, Zou X, Chen L, Ying LJ, Wu K, et al: The role of COX-2 in
mediating the effect of PTEN on BMP9 induced osteogenic
differentiation in mouse embryonic fibroblasts. Biomaterials.
35:9649–9659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niger C, Luciotti MA, Buo AM, Hebert C, Ma
V and Stains JP: The regulation of runt-related transcription
factor 2 by fibroblast growth factor-2 and connexin43 requires the
inositol poly-phosphate/protein kinase Cδ cascade. J Bone Miner
Res. 28:1468–1477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao M, Qiao M, Oyajobi BO, Mundy GR and
Chen D: E3 ubiquitin ligase Smurf1 mediates core-binding factor
alpha1/Runx2 degradation and plays a specific role in osteoblast
differentiation. J Biol Chem. 278:27939–27944. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hotchkiss CE, Latendresse J and Ferguson
SA: Oral treatment with retinoic acid decreases bone mass in rats.
Comp Med. 56:502–511. 2006.
|
|
26
|
Chen L, Jiang W, Huang J, He BC, Zuo GW,
Zhang W, Luo Q, Shi Q, Zhang BQ, Wagner ER, et al: Insulin-like
growth factor-2 (IGF-2) potentiates BMP-9-induced osteogenic
differentiation and bone formation. J Bone Miner Res. 25:2447–2459.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ali AA, Weinstein RS, Stewart SA, Parfitt
AM, Manolagas SC and Jilka RL: Rosiglitazone causes bone loss in
mice by suppressing osteoblast differentiation and bone formation.
Endocrinology. 146:1226–1235. 2005. View Article : Google Scholar
|
|
28
|
Duester G: Retinoid signaling in control
of progenitor cell differentiation during mouse development. Semin
Cell Dev Biol. 24:694–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lecka-Czernik B: Bone loss in diabetes:
Use of antidiabetic thiazolidinediones and secondary osteoporosis.
Curr Osteoporos Rep. 8:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aubert RE, Herrera V, Chen W, Haffner SM
and Pendergrass M: Rosiglitazone and pioglitazone increase fracture
risk in women and men with type 2 diabetes. Diabetes Obes Metab.
12:716–721. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang RN, Green J, Wang Z, Deng Y, Qiao M,
Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, et al: Bone
Morphogenetic Protein (BMP) signaling in development and human
diseases. Genes Dis. 1:87–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duester G: Retinoic acid synthesis and
signaling during early organogenesis. Cell. 134:921–931. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patatanian E and Thompson DF: Retinoic
acid syndrome: A review. J Clin Pharm Ther. 33:331–338. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berry DC and Noy N: All-trans-retinoic
acid represses obesity and insulin resistance by activating both
peroxisome proliferation-activated receptor beta/delta and retinoic
acid receptor. Mol Cell Biol. 29:3286–3296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Manolescu DC, Sima A and Bhat PV:
All-trans retinoic acid lowers serum retinol-binding protein 4
concentrations and increases insulin sensitivity in diabetic mice.
J Nutr. 140:311–316. 2010. View Article : Google Scholar
|
|
36
|
Dakshinamurti K: Vitamins and their
derivatives in the prevention and treatment of metabolic syndrome
diseases (diabetes). Can J Physiol Pharmacol. 93:355–362. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Felipe F, Bonet ML, Ribot J and Palou A:
Modulation of resistin expression by retinoic acid and vitamin A
status. Diabetes. 53:882–889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Y, Hou L, Tang F, Jiang W, Wang P,
Ding M and Deng H: Inducing embryonic stem cells to differentiate
into pancreatic beta cells by a novel three-step approach with
activin A and all-trans retinoic acid. Stem Cells. 23:656–662.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bose B, Shenoy SP, Konda S and Wangikar P:
Human embryonic stem cell differentiation into insulin secreting
β-cells for diabetes. Cell Biol Int. 36:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He BC, Chen L, Zuo GW, Zhang W, Bi Y,
Huang J, Wang Y, Jiang W, Luo Q, Shi Q, et al: Synergistic
antitumor effect of the activated PPARgamma and retinoid receptors
on human osteosarcoma. Clin Cancer Res. 16:2235–2245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen M, Huang HZ, Wang M and Wang AX:
Retinoic acid inhibits osteogenic differentiation of mouse
embryonic palate mesenchymal cells. Birth Defects Res A Clin Mol
Teratol. 88:965–970. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang A, Ding X, Sheng S and Yao Z:
Retinoic acid inhibits osteogenic differentiation of rat bone
marrow stromal cells. Biochem Biophys Res Commun. 375:435–439.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu G, Shu C, Cui L, Liu W and Cao Y:
Tissue-engineered bone formation with cryopreserved human bone
marrow mesenchymal stem cells. Cryobiology. 56:209–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
